Esophageal Neoplasms
Recent clinical, regulatory, research and industry developments relating to this disease.
Japanese Classification of Esophageal Cancer, 12th Edition: Part I.
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.
Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.
Esophageal cancer in China: Practice and research in the new era.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q1 2028.
Clinical MilestonesViewHide
- 2026-06-28PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer: A Randomized Multicenter Phase III TrialPrimary completion
- 2026-04-30Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Relapsed or Progressive Esophageal Squamous Cell CarcinomaPrimary completion
- 2025-12-01Prospective Single-arm, Exploratory, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemoradiotherapy in the Treatment of Advanced First-line Esophageal Phosphorous CarcinomaPrimary completion
- 2026-06-28ClinicalPD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer: A Randomized Multicenter Phase III TrialPrimary completion
- 2026-04-30ClinicalFruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Relapsed or Progressive Esophageal Squamous Cell CarcinomaPrimary completion
- 2025-12-01ClinicalProspective Single-arm, Exploratory, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemoradiotherapy in the Treatment of Advanced First-line Esophageal Phosphorous CarcinomaPrimary completion
- 2025-11-20ClinicalEfficacy and Safety of Combining Intestinal Low Dose Radiotherapy and PD-1/PD-L1 Inhibitors for Metastatic Malignant Solid Tumors After Acquired Resistance to Anti-PD1/PD-L1 TreatmentResults expected Q1 2028
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Esophageal Neoplasms14
- Adenocarcinoma7
- Stomach Neoplasms7
- Esophagogastric Junction4
- Claudins2
- Antibodies, Monoclonal1
- Antibodies, Monoclonal, Humanized1
- Antineoplastic Agents1
Leading journals6
- Clinical cancer research : an official journal of the American Association for Cancer Research3
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology3
- The New England journal of medicine3
- Esophagus : official journal of the Japan Esophageal Society2
- Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2
- JAMA oncology2
Leading researchers8
- Ajani JA6
- Shitara K5
- Enzinger PC4
- Ilson DH4
- Shah MA4
- Bang YJ3
- Hofstetter WL3
- Kitagawa Y3
Affiliations (unnormalised)6
- Memorial Sloan Kettering Cancer Center4
- National Cancer Center Hospital East4
- Seoul National University College of Medicine3
- Weill Cornell Medical College3
- Abramson Cancer Center at the University of Pennsylvania.2
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.2
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Esophageal neoplasms are tumors or cancer arising in the esophagus. The supplied literature frames them as clinically challenging and often aggressive malignancies that require multidisciplinary management.
The grounding supports Barrett's oesophagus and related early neoplasia as a precursor context for some esophageal cancers, but it does not provide a broader causal aetiology. It also notes that the literature covers etiology and genetics, but no specific causes are stated in the supplied material.
The literature describes abundant tumor antigens, including tumor-associated antigens and neoantigens, that can initiate dendritic cell-mediated cytotoxic T-cell responses early in disease. Tumors can then evade antitumor immunity through immune checkpoints, secreted factors, negative regulatory immune cells, and contributions from cancer-associated fibroblasts.
The supplied grounding does not specify general risk factors for esophageal neoplasms. It only supports Barrett's oesophagus and related early neoplasia as a relevant premalignant setting.
Management is multimodal and depends on stage. The literature supports endoscopic procedures for premalignant and early tumors, surgery for resectable disease, and neoadjuvant chemotherapy or chemoradiotherapy for locally advanced cancer; palliative treatment options are also available. The grounding also supports use of systemic chemotherapy, radiotherapy, targeted therapy, and immunotherapy classes in treatment discussions.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Tumors or cancer of the ESOPHAGUS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.